Business Description
Viracta Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92765F1084
Description
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.1 | |||||
| Equity-to-Asset | 0.32 | |||||
| Debt-to-Equity | 1.4 | |||||
| Debt-to-EBITDA | -0.55 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -33.7 | |||||
| 3-Year EPS without NRI Growth Rate | -36.9 | |||||
| 3-Year FCF Growth Rate | -33.5 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.58 | |||||
| 9-Day RSI | 39.76 | |||||
| 14-Day RSI | 42.83 | |||||
| 6-1 Month Momentum % | 68.78 | |||||
| 12-1 Month Momentum % | -14.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.43 | |||||
| Quick Ratio | 1.43 | |||||
| Cash Ratio | 1.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | -46.27 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -126.8 | |||||
| ROA % | -66.87 | |||||
| ROIC % | -366.04 | |||||
| ROC (Joel Greenblatt) % | -8161.84 | |||||
| ROCE % | -87.67 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.51 | |||||
| Price-to-Tangible-Book | 2.51 | |||||
| EV-to-EBIT | -0.22 | |||||
| EV-to-EBITDA | -0.23 | |||||
| EV-to-FCF | -0.27 | |||||
| Price-to-Net-Current-Asset-Value | 2.96 | |||||
| Price-to-Net-Cash | 2.12 | |||||
| Earnings Yield (Greenblatt) % | -454.55 | |||||
| FCF Yield % | -122.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VIRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Viracta Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.32 | ||
| Beta | 0.51 | ||
| Volatility % | 82.12 | ||
| 14-Day RSI | 42.83 | ||
| 14-Day ATR ($) | 0.1131 | ||
| 20-Day SMA ($) | 0.968808 | ||
| 12-1 Month Momentum % | -14.29 | ||
| 52-Week Range ($) | 0.43 - 2.38 | ||
| Shares Outstanding (Mil) | 39.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Viracta Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Viracta Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Viracta Therapeutics Inc Frequently Asked Questions
What is Viracta Therapeutics Inc(VIRX)'s stock price today?
The current price of VIRX is $0.83. The 52 week high of VIRX is $2.38 and 52 week low is $0.43.
When is next earnings date of Viracta Therapeutics Inc(VIRX)?
The next earnings date of Viracta Therapeutics Inc(VIRX) is 2024-05-08 Est..
Does Viracta Therapeutics Inc(VIRX) pay dividends? If so, how much?
Viracta Therapeutics Inc(VIRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers